Startups
1985
PALO BIOFARMA SLHarnesing the imnune system using adenosine modulators
Address
Carrer d'Ernest Lluch 32, 08302 Mataró, Spain
Finance Data
CERCA ownership
Barcelona, Spain
1992
Hospital del Mar Research Institute (HMRIB)
CERCA Center Contact
IÁ
Ismael Ávila
Hospital del Mar Research Institute (HMRIB)Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
The Vision of Palobiofarma is to discover the first marketed drug based on a selective adenosine receptor modulator.Palobiofarma focused internal resources on areas where lies the experience of the management team:
Virtual drug design
Medicinal Chemistry
In Vitro Pharmacology of adenosine
Physico-chemical characterization of the compounds
Intellectual Property
The remaining activities needed for the full compound characterization and the nomination of a development candidate, such as the pharmacology and toxicology tests, are carried out through partnerships with various companies (CROs), Research Centres and Universities.
Virtual drug design
Medicinal Chemistry
In Vitro Pharmacology of adenosine
Physico-chemical characterization of the compounds
Intellectual Property
The remaining activities needed for the full compound characterization and the nomination of a development candidate, such as the pharmacology and toxicology tests, are carried out through partnerships with various companies (CROs), Research Centres and Universities.
Product description
PBF-677 - Potent and selective, GI-restricted adenosine A3 receptor antagonist as first in class oral treatment for IBD. Phase I in healthy volunteers has been completed and a POC trial in ulcerative colitis patients is in progress.
PBF-1650 - Potent and selective, orally bioavailable adenosine A3 receptor antagonist for the treatment of autoimmune diseases like psoriasis and NASH. Phase I studies in healthy volunteers are in progress.
PBF-999 - Dual Adenosine A2a receptor antagonist / Phosphodiesterase 10 (PDE-10) inhibitor for the treatment of tumors, especially for “cold tumors”, as for example colon cancers. A Phase I dose escalation study in patients with biopsiable solid tumors is in progress
PBF-1129 - Potent and selective adenosine A2b receptor antagonist as first in class oral treatment for Idiopathic Pulmonary Fibrosis and lung cancer. Phase I clinical trials in healthy volunteers has been completed with the compound and a Phase I dose escalation study in lung cancer patients is in progress.
PBF-680 - Potent, non-BBB permeable, adenosine A1 receptor antagonist as a first in class oral treatment of respiratory diseases as asthma and COPD. The compound has demonstrated excellent safety, tolerability, and pharmacokinetic profile in humans following administration of single and multiple ascending. A POC trial in asthmatics has been completed with positive results. Phase II clinical in mild to moderate asthmatics are in progress.
PBF-509 - Potent, non-furan containing adenosine A2A receptor antagonist for as novel checkpoint inhibitor for the treatment of solid tumors. The compound has been out-licensed to Novartis through an agreement signed in 2015 and is facing Phase II clinical trials in nine different tumor types.
PBF-1650 - Potent and selective, orally bioavailable adenosine A3 receptor antagonist for the treatment of autoimmune diseases like psoriasis and NASH. Phase I studies in healthy volunteers are in progress.
PBF-999 - Dual Adenosine A2a receptor antagonist / Phosphodiesterase 10 (PDE-10) inhibitor for the treatment of tumors, especially for “cold tumors”, as for example colon cancers. A Phase I dose escalation study in patients with biopsiable solid tumors is in progress
PBF-1129 - Potent and selective adenosine A2b receptor antagonist as first in class oral treatment for Idiopathic Pulmonary Fibrosis and lung cancer. Phase I clinical trials in healthy volunteers has been completed with the compound and a Phase I dose escalation study in lung cancer patients is in progress.
PBF-680 - Potent, non-BBB permeable, adenosine A1 receptor antagonist as a first in class oral treatment of respiratory diseases as asthma and COPD. The compound has demonstrated excellent safety, tolerability, and pharmacokinetic profile in humans following administration of single and multiple ascending. A POC trial in asthmatics has been completed with positive results. Phase II clinical in mild to moderate asthmatics are in progress.
PBF-509 - Potent, non-furan containing adenosine A2A receptor antagonist for as novel checkpoint inhibitor for the treatment of solid tumors. The compound has been out-licensed to Novartis through an agreement signed in 2015 and is facing Phase II clinical trials in nine different tumor types.